Alto: a computational, biomarker-based approach to neuropsychiatry

With $40 million in funding thus far, Stanford spinout Alto is developing psychiatric therapies for targeted populations using biomarkers it has identified by applying machine learning to electroencephalography data.

The two-year-old start-up emerged from stealth mode Thursday with a $32 million series A round that builds on $8 million in seed funding. Leading the round was Apeiron Investment Group, the family office of entrepreneur Christian Angermayer...